Market Summary
Global Ulcerative Colitis Market Overview
As per MRFR analysis, the Ulcerative Colitis Market Size was estimated at 7.96 (USD Billion) in 2024. The Ulcerative Colitis Market Industry is expected to grow from 8.37 (USD Billion) in 2025 to 13.12 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.12% during the forecast period (2025 - 2034).The rise in the incidence of inflammatory gastrointestinal illness and the prevalence of inflammatory bowel disease are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Janssen Global Services, LLC, for example, in May 2023, issued safety and efficacy data of Tremyfa, a Phase III trial in adults with moderately to severely active ulcerative colitis (UC). Therefore, there is the expectation that this heavy focus on developing new drugs to be used as treatments will enhance the market’s growth in the coming days. Equally important, this has also propelled the growth of the market with regard to medication approval.
Merck & Co., Inc. agreed in April 2023 to acquire Prometheus Biosciences for $200 cash per share, or approximately $10.8 billion equity value. Accordingly, this would enable Prometheus Biosciences to maximize the potential of PRA023, which is a novel late-stage candidate for ulcerative colitis and other diseases, including Crohn’s disease associated with autoimmune disorders.
Takeda Pharmaceutical Company Limited received approval in March 2023 from the Japanese Ministry of Health, Labour and Welfare for Entyvio Pens (vedolizumab) maintenance therapy in moderate-to-severe UC.
In August 2022, Teva Pharmaceutical Industries initiated a phase II clinical trial aimed at determining TEV-48574 effectiveness and safety profile among patients suffering from Ulcerative Colitis. As such, these new research studies assist companies in spreading out their product lines leading towards augmenting regional market development over estimated duration.
Arena Pharmaceuticals was purchased by Pfizer– an American multinational corporation operating in the biotechnology field- an American biopharmaceutical company in March 2022. This acquisition was aimed at connecting Arena Pharmaceuticals’ remarkable pipeline and history with Pfizer’s Immunology and Inflammation Healing Domain, thus creating more reasons to improve the living of patients suffering from immuno-inflammatory disorders.
Ulcerative Colitis Market Trends
- The rise in the incidence of inflammatory gastrointestinal illness boosts the market growth
The rise in the incidence of inflammatory gastrointestinal illness, an increase in ulcerative colitis cases, and the development of medications for ulcerative colitis treatment by many important companies are driving the growth of the ulcerative colitis market. A 2019 ulcerative survey by Mark D. Basson found that 1 million Americans had ulcerative colitis. The reason for the rapid expansion of ulcerative colitis treatments is their high prevalence.
The demand for ulcerative colitis is anticipated to grow as the prevalence of inflammatory bowel disease rises. The introduction of biosimilars is promoting market expansion. Biosimilars are anticipated to be more affordable and available in developing nations than big pharmacies. One of the reasons for the introduction of new biosimilars is the anticipated patent expiration of some medications. This segment is expected to grow due to important players' increased involvement in creating domain-related products. The introduction of novel therapies with an improved clinical profile and patient-friendly RoA, as well as the increased uptake of targeted and advanced therapies, are the factors causing the growth.
Increased incidences of inflammatory gastrointestinal disorders, an increase in ulcerative colitis cases, and the development of medications for the condition by numerous major players are the main factors driving the growth of the market for ulcerative colitis Due to the increasing cost of healthcare ly and the increased efforts of governmental and non-governmental organizations to conduct biologics research, the market for ulcerative colitis treatments is also expanding.
Additionally, in a research study by Wing Yan Mak et al., 23–34% of ulcerative colitis patients who presented had proctitis, according to a study published in the Journal of Gastroenterology and Hepatology in 2020. Additionally, Bristol Myers Squibb received authorization from the U. in May 2021. S. the Food and Drug Administration approves Zeposia to treat adults with moderately to severely active ulcerative colitis, a long-term inflammatory bowel disease. As a result, the market opportunity for ulcerative colitis increased as new drugs were being developed. It has enhanced the Ulcerative Colitis market CAGR across the globe in recent years.
Ulcerative Colitis Market Segment Insights
Ulcerative Colitis Type Insights
Based on fusion type, the market segments of Ulcerative Colitis includes Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis. The Ulcerative Proctitis segment held the majority share in 2022 contribution concerning the Ulcerative Colitis market revenue. The number of Americans with ulcerative colitis (UC) is estimated to be around 1 million. The prevalence rate is 35-100 cases per 100,000 people, and the annual incidence is 10.4-12 cases per 100,000 people. Three times as many people have ulcerative colitis as Crohn's disease.
Ulcerative Colitis Medications Insights
Based on Medications, the Ulcerative Colitis market segmentation includes 5-Aminosalicylates, Steroids, Purine Analogs, Immunomodulators, and Biologics. The Steroids segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2032. Steroids lessen redness and swelling (inflammation) when taken in doses greater than your body naturally produces. Inflammatory diseases like asthma and eczema may benefit from this. The immune system, the body's natural defense against disease and infection, is less active due to steroid implants for Ulcerative Colitis, positively impacting the market growth.
Figure 1 Ulcerative Colitis Market, by Medications, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Ulcerative Colitis Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Ulcerative Colitis market accounted for USD 3.2976 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The healthcare market in North America is expanding significantly. The area has established itself as a hub for technological innovation and change. The Asia Pacific region is anticipated to experience significant growth at a CAGR of 6.5 percent through the forecast period. The rising consumer health awareness and increasing healthcare expenditure in this region drive market growth. According to a study on ulcerative colitis by Marc D. Basson in 2019, in the U. S., One million individuals have ulcerative colitis. The primary driver behind the creation of drugs to treat ulcerative colitis is its prevalence. As a result, as the prevalence of inflammatory bowel disease rises, so does the demand for ulcerative colitis. This is expected to support the market's expansion for ulcerative colitis.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 Ulcerative Colitis Market Share By Region 2022 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe’s Ulcerative Colitis market accounts for the second-largest market share a research study by Wing Yan Mak et al. 23–34% of ulcerative colitis patients who presented had proctitis, according to a study published in the Journal of Gastroenterology and Hepatology in 2020. Additionally, Bristol Myers Squibb received authorization from the U. in May 2021. The Food and Drug Administration approves Zeposia to treat adults with moderately to severely active ulcerative colitis, a long-term inflammatory bowel disease. As a result, the market opportunity for ulcerative colitis increased as new drugs were being developed. Further, the Germany market of Ulcerative Colitis held the largest market share, and the UK market of Ulcerative Colitis was the fastest-growing market in the European region.
The Asia-Pacific Ulcerative Colitis Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to increased rates of osteoarthritis and degenerative disc disease, the rapidly growing medical tourism industry, and rising healthcare costs. Moreover, the China market of Ulcerative Colitis held the largest market share, and the India market of Ulcerative Colitis was the fastest-growing market in the Asia-Pacific region.
Ulcerative Colitis Key Market Players & Competitive Insights
Major market players are spending much on R&D to increase their product lines, which will help the market of Ulcerative Colitis grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Ulcerative Colitis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Ulcerative Colitis industry to benefit clients and expand the market sector. The Ulcerative Colitis industry has provided medicine with some of the most significant benefits in recent years. The Ulcerative Colitis markets major players such as Salix Pharmaceuticals, Abbott Laboratories, Mitsubishi Tanabe Pharma Corporation, Celgene Corporation, InDex Pharmaceuticals Holding AB, BioLineRx Ltd, Sanofi Aventis A/S, Merck & Co, Eli Lilly, Johnson & Johnson, and others are working on expanding the market demand by investing in research and development activities.
Key Companies in the Ulcerative Colitis market include
- Salix Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation
- Celgene Corporation
- InDex Pharmaceuticals Holding AB
- BioLineRx Ltd
- Sanofi Aventis A/S
- Eli Lilly
- Johnson & Johnson
Sanofi Aventis A/S We are a cutting-edge healthcare organization whose sole motivation is to pursue scientific breakthroughs to enhance people's quality of life. Our teams work to change the way medicine is done so that patients can have the unthinkable made possible. Millions of people benefit from our life-saving vaccines and potentially life-changing treatments, and some of the world's poorest nations have affordable access to our medications.
Also, Abbott Laboratories (US) We are committed to realizing the promise of human potential in all contexts, facets, and phases of life. We consider that promise to be largely dependent on health. We can accomplish anything when we are in good health. And because of this, we will always strive to support people in achieving their optimal level of health at every stage of their lives. This is how we live out that conviction every day.
Ulcerative Colitis Industry Developments
May 2023: Janssen Global Services, LLC, for example, in May 2023, issued safety and efficacy data of Tremyfa, a Phase III trial in adults with moderately to severely active ulcerative colitis (UC). Therefore, there is the expectation that this heavy focus on developing new drugs to be used as treatments will enhance the market’s growth in the coming days. Equally important, this has also propelled the growth of the market with regard to medication approval.
April 2023: Merck & Co., Inc. agreed in April 2023 to acquire Prometheus Biosciences for $200 cash per share, or approximately $10.8 billion equity value. Accordingly, this would enable Prometheus Biosciences to maximize the potential of PRA023, which is a novel late-stage candidate for ulcerative colitis and other diseases, including Crohn’s disease associated with autoimmune disorders.
March 2023: Takeda Pharmaceutical Company Limited received approval in March 2023 from the Japanese Ministry of Health, Labour and Welfare for Entyvio Pens (vedolizumab) maintenance therapy in moderate-to-severe UC.
August 2022: Teva Pharmaceutical Industries initiated a phase II clinical trial aimed at determining TEV-48574 effectiveness and safety profile among patients suffering from Ulcerative Colitis. As such, these new research studies assist companies in spreading out their product lines leading towards augmenting regional market development over estimated duration.
March 2022: For the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, the United States Food and Drug Administration (FDA) approved AbbVie's RINVOQ (upadacitinib).
April 2022: Company Pfizer. reported the encouraging topline findings from a Phase 3 study of stasimon, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator being developed for the treatment of moderately to severely active ulcerative colitis (UC).
November 2020: Takeda Pharmaceutical Company Limited began a phase III clinical trial in Japan to evaluate the effectiveness and safety of intravenous (IV) Vedolizumab in Japanese patients with moderate to severe ulcerative colitis.
November 2020: The players' growing focus on creating therapeutic drugs is anticipated to boost the future market growth.
September 2020: Zeposia (ozanimod) was approved for marketing by the European Commission to treat adults with moderately to severely active ulcerative colitis (UC) who have experienced an insufficient response, lost response, or are intolerant to either conventional therapy or a biologic agent.
Ulcerative Colitis Market Segmentation
Ulcerative Colitis Type Outlook
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
Ulcerative Colitis Medication Outlook
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
Ulcerative Colitis Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Market Size & Forecast
| Attribute/Metric | Details |
|
Market Size 2024 |
7.96 (USD Billion) |
|
Market Size 2025 |
8.37 (USD Billion) |
|
Market Size 2034 |
13.12 (USD Billion) |
|
Compound Annual Growth Rate (CAGR) |
5.12 % (2025 - 2034) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Base Year |
2024 |
|
Market Forecast Period |
2025 - 2034 |
|
Historical Data |
2020 - 2024 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Medication, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Salix Pharmaceuticals, Abbott Laboratories, Mitsubishi Tanabe Pharma Corporation, Celgene Corporation, InDex Pharmaceuticals Holding AB, BioLineRx Ltd, Sanofi Aventis A/S, Merck & Co, Eli Lilly, Johnson & Johnson |
| Key Market Opportunities | Growth in demand as the prevalence of inflammatory bowel disease rises |
| Key Market Dynamics | Increased incidences of inflammatory gastrointestinal disorders Increase in ulcerative colitis cases |
Major Players
Ulcerative Colitis Market Segmentation
Ulcerative Colitis Type Outlook (USD Billion, 2019-2032)
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
Ulcerative Colitis Medication Outlook (USD Billion, 2019-2032)
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
Ulcerative Colitis Regional Outlook (USD Billion, 2019-2032)
- North America Outlook (USD Billion, 2019-2032)
- North America Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- North America Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- US Outlook (USD Billion, 2019-2032)
- US Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- US Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- CANADA Outlook (USD Billion, 2019-2032)
- CANADA Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- CANADA Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Europe Outlook (USD Billion, 2019-2032)
- Europe Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Europe Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Germany Outlook (USD Billion, 2019-2032)
- Germany Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Germany Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- France Outlook (USD Billion, 2019-2032)
- France Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- France Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- UK Outlook (USD Billion, 2019-2032)
- UK Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- UK Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- ITALY Outlook (USD Billion, 2019-2032)
- ITALY Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- ITALY Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- SPAIN Outlook (USD Billion, 2019-2032)
- Spain Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Spain Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Rest of Europe Outlook (USD Billion, 2019-2032)
- Rest of Europe Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- REST OF EUROPE Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Asia-Pacific Outlook (USD Billion, 2019-2032)
- Asia-Pacific Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Asia-Pacific Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- China Outlook (USD Billion, 2019-2032)
- China Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- China Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Japan Outlook (USD Billion, 2019-2032)
- Japan Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Japan Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- India Outlook (USD Billion, 2019-2032)
- India Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- India Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Australia Outlook (USD Billion, 2019-2032)
- Australia Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Australia Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)
- Rest of Asia-Pacific Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Rest of Asia-Pacific Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Rest of the World Outlook (USD Billion, 2019-2032)
- Rest of the World Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Rest of the World Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Middle East Outlook (USD Billion, 2019-2032)
- Middle East Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Middle East Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Africa Outlook (USD Billion, 2019-2032)
- Africa Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Africa Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Latin America Outlook (USD Billion, 2019-2032)
- Latin America Ulcerative Colitis by Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
- Latin America Ulcerative Colitis by Medication
- 5-Aminosalicylates
- Steroids
- Purine Analogs
- Immunomodulators
- Biologics
- Rest of the World Ulcerative Colitis by Type
- Asia-Pacific Ulcerative Colitis by Type
- Europe Ulcerative Colitis by Type
- North America Ulcerative Colitis by Type
Leave a Comment